Radhika Verma, MD
Sleep Medicine · Orange City, FLNPI 1801898325
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,005 of the $14,132 with a category attached, or 77.9%. It is spread thinly across 45 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $4,178 and has fallen 83.5% since, to $691 in 2025.
Across 504 payments — averaging $28.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- ZOLL Respicardia, Inc.$2K
- AstraZeneca$1K
- Sanofi$1K
- Jazz Pharmaceuticals Inc.$862
- Harmony Biosciences LLC$846
- plus $6K from 39 others
What the payments were for
- Consulting fees$8226%
- Speaking & faculty fees$7225%
- Travel & lodging$1,0507%
- Food & beverage$11,00578%
- Education$5194%
- Entertainment$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$1,672
- DUPIXENT$1,188
- Yupelri$722
- TEZSPIRE$400
- FASENRA$395
- Prolastin-C Liquid$277
- XYWAV$276
- BREZTRI$265
- ACTHAR$229
- Xembify$158
- IMFINZI$146
- AIRSUPRA$146
- FLOWTRIEVER CATHETER, S$138
- CT THROMBECTOMY SYSTEM KIT$138
- Spin$124
- TAGRISSO$124
- Monarch Platform$123
- NUCALA$122
- Inspire Upper Airway Stimulation System$120
- AMPLATZER$119
How this compares
$14,132 in reported general payments places this provider in the 85th percentile of 77 sleep medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 719 | $581,171 |
| OfevNintedanib Esylate | 19 | $256,344 |
| WakixPitolisant Hcl | 13 | $196,675 |
| Dupixent SyringeDupilumab | 35 | $138,079 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 111 | $91,733 |
| Breo ElliptaFluticasone/Vilanterol | 174 | $90,061 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 91 | $71,551 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 121 | $68,982 |
| Spiriva RespimatTiotropium Bromide | 82 | $60,241 |
| SymbicortBudesonide/Formoterol Fumarate | 145 | $39,646 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 181 | $24,796 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 448 | $11,879 |
| Arnuity ElliptaFluticasone Furoate | 26 | $6,937 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $6,714 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $6,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,836 | $753,6351,054 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $675 | $388,136192 claims |
| Harmony Biosciences LLCWakix | $846 | $196,67513 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,480 | $131,379256 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $16 | $3,86312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 77 sleep medicine providers in Florida.
Other sleep medicine in Orange City
- Shahana MasoodOrange City$6K
- Jeremy McConnellBradenton$615K
- Edward MezerhaneMiami$537K
- Shane DrahosWinter Garden$317K
- Kunal AgarwalSarasota$153K
- Camilo RuizFort Lauderdale$136K
- Sergio JaramilloMiami$32K
- Carlos Ramirez MejiaMiami$25K
- Luis OrtizSt Petersburg$24K
- Harneet WaliaMiami$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.